Glutathione synthesis
SC Lu - Biochimica et Biophysica Acta (BBA)-General Subjects, 2013 - Elsevier
BACKGROUND: Glutathione (GSH) is present in all mammalian tissues as the most
abundant non-protein thiol that defends against oxidative stress. GSH is also a key …
abundant non-protein thiol that defends against oxidative stress. GSH is also a key …
Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review
M Bagherniya, V Nobili, CN Blesso… - Pharmacological …, 2018 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver diseases, and is closely
related to metabolic syndrome and its related conditions, diabetes mellitus and dyslipidemia …
related to metabolic syndrome and its related conditions, diabetes mellitus and dyslipidemia …
S-adenosylmethionine in Liver Health, Injury, and Cancer
SC Lu, JM Mato - Physiological reviews, 2012 - journals.physiology.org
S-adenosylmethionine (AdoMet, also known as SAM and SAMe) is the principal biological
methyl donor synthesized in all mammalian cells but most abundantly in the liver …
methyl donor synthesized in all mammalian cells but most abundantly in the liver …
N-acetyl cysteine treatment mitigates biomarkers of oxidative stress in different tissues of bile duct ligated rats
Cholestasis is a multifaceted clinical complication. Obstructive jaundice induced by bile duct
ligation (BDL) is known as an animal model to investigate cholestasis and its associated …
ligation (BDL) is known as an animal model to investigate cholestasis and its associated …
[HTML][HTML] S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis
T Guo, L Chang, Y Xiao, Q Liu - PloS one, 2015 - journals.plos.org
It has been well established that S-adenosyl-L-methionine (SAMe) is the principal methyl
donor in methyltransferase reactions and that SAMe supplementation restores hepatic …
donor in methyltransferase reactions and that SAMe supplementation restores hepatic …
[HTML][HTML] Dysregulation of glutathione synthesis in liver disease
SC Lu - Liver Research, 2020 - Elsevier
Glutathione (GSH), a tripeptide that is present in all mammalian tissues, is especially highly
concentrated in the liver. GSH synthesis occurs via two adenosine triphosphate (ATP) …
concentrated in the liver. GSH synthesis occurs via two adenosine triphosphate (ATP) …
Bezafibrate treatment: a new medical approach for PBC patients?
T Kanda, O Yokosuka, F Imazeki, H Saisho - Journal of gastroenterology, 2003 - Springer
Background. A new medical approach to primary biliary cirrhosis (PBC) has been desired.
We investigated the feasibility of using combination ursodeoxycholic acid (UDCA) …
We investigated the feasibility of using combination ursodeoxycholic acid (UDCA) …
Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis
CY Chen, PN Tsao, HL Chen, HC Chou… - The Journal of …, 2004 - Elsevier
OBJECTIVE: To determine the effect of ursodeoxycholic acid (UDCA) in very-low-birth-
weight (VLBW) infants with parenteral nutrition-associated cholestasis (PNAC). STUDY …
weight (VLBW) infants with parenteral nutrition-associated cholestasis (PNAC). STUDY …
Copper induces hepatocyte injury due to the endoplasmic reticulum stress in cultured cells and patients with Wilson disease
S Oe, K Miyagawa, Y Honma, M Harada - Experimental cell research, 2016 - Elsevier
Copper is an essential trace element, however, excess copper is harmful to human health.
Excess copper-derived oxidants contribute to the progression of Wilson disease, and …
Excess copper-derived oxidants contribute to the progression of Wilson disease, and …
High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis
Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid
(UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of …
(UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of …